Healthcare M&A: What Your Compensation Committee Should Be Doing Now

On April 20, 2023, Cravath prepared a memo entitled “The Healthcare M&A Surge Is Here: What Your Compensation Committee Should Be Doing Now.” The memo outlines key human capital considerations for Boards of Directors and management of pharma and biotech companies weighing a potential M&A transaction, including strategies to retain key employees, severance protections in the event of potential synergies and strategies to manage the potential impact of 280G excise taxes.

Please click here to read the memo.